Introduction
============

Coronary heart disease (CHD) is a leading cause of morbidity and mortality globally \[[@B1],[@B2]\]. It is well established that reducing serum low-density-lipoprotein-cholesterol (LDL-C) reduces risk for CHD \[[@B3]\]. Lifestyle modifications to reduce CHD risk include increased consumption of viscous soluble dietary fiber \[[@B4]\]. Oats are a good source of soluble fiber, the major component of which is (1→3)(1→4)-β-D-glucan, or β-glucan. Many, but not all studies have shown that oat-containing food products reduce serum LDL-C \[[@B5]\]. We showed that the LDL-C-lowering effect of oat β-glucan depended on its viscosity \[[@B6]\] which, in turn, depends on molecular weight (MW) and solubility \[[@B7]\]; 3-4 g/d of oat β-glucan with MW ranging from 5.3 × 10^5^to 2.2 × 10^6^g/mol significantly reduced LDL-C by 4.8 to 6.5%, but 4 g/d of oat β-glucan with MW 2.1 × 10^5^g/mol had no significant effect \[[@B6]\]. Since there is evidence that the prevalence of blood lipid abnormalities and other CHD risk factors varies in different ethnic groups \[[@B8]\] and that the LDL-C-lowering effect of statins differs by ethnicity \[[@B9],[@B10]\], we examined our data to see if the effect of oat β-glucan on LDL-C varied by ethnicity.

Methods
=======

The methodology and main results of the trial have been reported elsewhere \[[@B6]\]. Briefly, we conducted a double-blind, randomized, parallel design, controlled clinical trial at 2 contract-research-organizations and 3 university nutrition research centers. Participants were healthy men and women aged 35 to 70 yr with body mass index (BMI) ≥ 18.5 and ≤ 40.0 kg/m^2^and fasting serum LDL-C ≥ 3.0 and ≤5.0 mmol/L; 786 subjects were screened, 400 did not meet the inclusion criteria, 19 declined to participate, 367 were randomly assigned to one of the 5 treatments and 22 discontinued treatment before the end of the trial. Written informed consent was obtained from all subjects. The protocol was approved by the ethics review committee at each participating institution. The trial was registered at <http://www.clinicaltrials.gov> with identifier number NCT00981981.

After eligibility had been determined subjects, stratified by center and by LDL-C (stratum; low, 3.0 ≤ LDL-C ≤ 3.8 mmol/L; or high, 3.8 \< LDL-C ≤ 5.0 mmol/L), were randomly assigned to receive a ready-to-eat wheat bran cereal (Control), or oat cereal providing a total of 3 g High-MW (3 H, MW = 22.5 × 10^5^g/mol), 4 g Medium-MW (4 M, MW = 8.5 × 10^5^g/mol), 3 g Medium-MW (3 M, MW = 5.3 × 10^5^g/mol) or 4 g Low-MW (4 L, MW = 2.1 × 10^5^g/mol) oat β-glucan per day for 4 weeks. Cereals were packed into air-tight foil sachets each containing half the daily dose (10-14 g) and labelled with a code. After the baseline blood sample, subjects were given a 1-week supply (14 sachets) of their assigned cereal and instructed to consume 2 sachets daily, one with breakfast and one with another meal or snack. Otherwise, subjects maintained their usual diets and other lifestyle habits throughout the study. The daily dose of cereals contained 234-339 kJ, 3-4 g protein, 1 g fat, 9-13 g carbohydrate and 6-8 g total fiber \[[@B6]\]. Fasting blood was obtained weekly for analysis of total and HDL cholesterol, triglycerides and calculated LDL-C.

Here we report the results for LDL-C in subjects based on their ethnicity. Ethnicity was determined based on the subjects\' own classification of themselves as Caucasian, Black, Aboriginal, South Asian, Arab/West Asian, Filipino, South East Asian, Hispanic, Chinese, Japanese, Korean or other. Since the number of subjects in each non-Caucasian category was too small for meaningful comparisons, for the purposes of this analysis, subjects were classified as either Caucasian or non-Caucasian.

Statistical analyses were performed using SAS (SAS 9.2, XP-Pro, 2002-2008, SAS Institute, Inc., Cary, NC) on an intent-to-treat basis using all available data from the 366 subjects randomly assigned to treatments and whose ethnicity could be identified (one of the 367 randomized subjects was excluded for missing data on ethnicity). For all 5 treatments, the main effects of treatment and ethnicity and the treatment × ethnicity interaction on week 4 LDL-C was examined using analysis of covariance (ANCOVA), controlling for baseline LDL-C and stratum; the effects of sex, center, age, waist circumference and BMI were tested but not included in the final model because they had no significant effect (P \> 0.1). Post hoc testing was performed after demonstration of significant heterogeneity by ANCOVA using Fisher\'s LSD. The criterion for declaring a statistically significant difference was 2-tailed p \< 0.05.

Results
=======

The 296 Caucasian participants were older than the 70 non-Caucasians but were similar in sex, BMI and blood lipids at baseline (Table [1](#T1){ref-type="table"}). The total number (% non-Caucasian), respectively, assigned to the 5 treatments were: Control, 87 (15%); 3 H, 86 (22%), 4 M, 67 (25%); 3 M, 63 (14%), and 4 L 63 (19%) (p = 0.39). For most, but not all, treatments, LDL-C tended to respond within 1-2 weeks of starting treatment and remain stable over the last 2 weeks of the study (Figure [1](#F1){ref-type="fig"}). The results for ANCOVA for LDL-C at week 4 showed significant effects of baseline LDL-C (p \< 0.001), stratum (p \< 0.001) and treatment (p = 0.003) but no significant effect of ethnicity (p = 0.74) and no treatment × ethnicity interaction (p = 0.34). The latter indicates that the effects of the 5 treatments on LDL-C did not differ significantly in Caucasians vs non-Caucasians. Compared to Control, 3 H and 4 M reduced LDL-C significantly in Caucasians and 3 H, 3 M and 4 M reduced LDL-C significantly in non-Caucasians (Figure [2](#F2){ref-type="fig"}). 4 L had no effect in either group. When the results of the bioactive treatments (3 H, 4 M and 3 M) were pooled and compared to control, bioactive oat β-glucan reduced LDL-C by a mean (95% CI) of 0.18 (0.06, 0.31) mmol/L (4.8%, p = 0.004) in Caucasians and by 0.37 (0.09, 0.65) mmol/L (10.3%, p = 0.008) in non-Caucasians; the difference between Caucasians and non-Caucasians was not significant (p = 0.24).

###### 

Characteristics of Caucasian and Non-Caucasian subjects at baseline.

                               Caucasian   Non-Caucasian                 
  ---------------------------- ----------- --------------- ------ ------ ----------
  Age (yr)                     53.5        9.1             47.0   7.9    \< 0.001
  Body Mass Index (kg/m^2^)    27.5        4.2             27.5   4.3    ns
  Waist circumference (cm)     93.3        21.1            90.8   12.2   ns
  Total cholesterol (mmol/L)   5.99        0.72            5.77   0.77   ns
  Triglycerides (mmol/L)       1.54        0.84            1.58   0.93   ns
  HDL cholesterol              1.49        0.41            1.38   0.40   ns
  LDL cholesterol              3.78        0.68            3.64   0.82   ns

![**Time course of unadjusted percent changes from baseline of LDL-C in Caucasian (C) and non-Caucasian (N) subjects randomly assigned to consume the control cereal (Cont, C:N n = 74:13), or cereals containing 4 g low-MW oat β-glucan (4 L, C:N n = 51:12), 3 g medium-MW oat β-glucan (3 M, C:N n = 54:9), 4 g medium-MW oat β-glucan (4 M, C:N n = 50:17) or 3 g high-MW oat β-glucan (3 H, C:N n = 67:19) daily for 4 weeks**. Values represent means ± SEM.](1475-2891-10-130-1){#F1}

![**Difference in LDL-C, adjusted for baseline, in Caucasian (C, filled bars) and non-Caucasian (N, open bars) subjects after 4 weeks on cereals containing 4 g low-MW oat β-glucan (4 L, C:N n = 51:12), 3 g medium-MW oat β-glucan (3 M, C:N n = 54:9), 4 g medium-MW oat β-glucan (4 M, C:N n = 50:17) or 3 g high-MW oat β-glucan (3 H, C:N n = 67:19) daily versus mean adjusted-LDL-C after 4 weeks on Control in the same ethnic group**. Values are means ± 95% CI.](1475-2891-10-130-2){#F2}

Discussion
==========

There is concern that the burden of chronic diseases is neglected globally especially in low- and middle-income countries \[[@B11]\]. Serum cholesterol, a marker of CHD risk, has fallen over the last 30 years in high-income countries but has not changed significantly or even risen in low- and middle-income countries \[[@B12]\]. To tackle the burden of chronic disease a combination of strategies may be used to promote healthy lifestyles \[[@B13]\]. It was suggested that private-sector initiatives (such as high-fiber breakfast-cereals) may be useful but more evidence on their effectiveness is needed \[[@B13]\]. In this context, there is increasing acceptance that viscous soluble fiber lower serum cholesterol, with claims allowed in Malaysia for products containing oat β-glucan \[[@B14]\] and Japan for products containing psyllium \[[@B15]\]. However, the evidence for these effects comes largely from studies in Caucasians. Thus, our results showing that oat β-glucan lowered LDL-C in non-Caucasians may be helpful to support global efforts to reduce CHD risk.

Since our study was not designed to compare the LDL-C-lowering effect of oat β-glucan in different ethnic groups, the results should be interpreted with caution. Also, we pooled non-Caucasian ethnic groups amongst whom differences may exist. Nevertheless, with 19% of subjects being non-Caucasian, few, if any studies to date on the cholesterol-lowering effects of oat β-glucan include a population as large and diverse as ours. Bioactive oat β-glucan tended to lower LDL-C more in non-Caucasians than Caucasians (0.37 vs 0.18 mmol/L; or 10.3 vs 4.8%), but the difference was not statistically significant. However, the study only had 34% power to detect a significant difference between Caucasians and non-Caucasians and, thus, was underpowered. Nevertheless, our results are consistent with the tendency for 3 g oat β-glucan in a ready-to-eat cereal to reduce LDL-C more in Hispanic Americans \[[@B16]\] than in predominantly (86%) Caucasian subjects \[[@B17]\], 7.5 vs 4.4% relative to control. Therefore, this effect may warrant further study.

Conclusion
==========

We conclude that oat β-glucan reduces LDL-C in Caucasians and non-Caucasians, but there was insufficient power to determine if the magnitude of LDL-C-lowering differs by ethnicity.
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